24-hour IOP-lowering Effect of Brimonidine 0.1%

Completed · Phase 4

Conditions studied: Open-angle Glaucoma, Ocular Hypertension

In brief

This study will evaluate the efficacy and safety of brimonidine 0.1% three-times daily in patients with glaucoma or ocular hypertension

Key facts

Study ID

NCT00457795

Run by

Allergan

People needed

15

Starts

2006-12-01

Expected to finish

2009-02-01

Last updated by the study team

2011-11-24

Who can join

Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• patients with open-angle glaucoma or ocular hypertension

You may not qualify if…

• allergy to brimonidine
• inability to complete 24 hour stay for monitoring

Where it is running

• Study site — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.